QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML

• ClinicalTrials.gov Identifier: NCT03050216
• Recruitment Status: Completed
• First Posted: February 10, 2017
• Results First Posted: November 27, 2020
• Last Update Posted: July 18, 2023
• Sponsor: Masonic Cancer Center, University of Minnesota
• Information provided by (Responsible Party): Masonic Cancer Center, University of Minnesota

Study Description

Brief Summary:

This is a multi-institutional Simon's optimal two-stage phase II trial of CD3/CD19 depleted, ALT-803 activated, haploidentical donor NK cells and subcutaneous ALT-803 given after lymphodepleting chemotherapy (CY/FLU) for the treatment of refractory or released acute myelogenous leukemia (AML).

Condition or disease	Intervention/treatment	Phase
Acute Myeloid Leukemia	Biological: ALT-803	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
• Actual Study Start Date: May 16, 2017
• Actual Primary Completion Date: December 15, 2019
• Actual Study Completion Date: December 15, 2019

Arms and Interventions

Arm

Intervention/treatment

Experimental: Cy, FLU, Haplo NK and ALT-803; Preparative Regimen of Fludarabine and Cyclophosphamide ALT-803 Activation of Donor NK Cells ALT-803 to Facilitate NK Cell Survival and Expansion

Biological: ALT-803; Preparative Regimen: Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 ALT-803 Stimulated Donor NK Cells: The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0. ALT-803 to Facilitate NK Cell Survival and Expansion: ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total

Outcome Measures

Primary Outcome Measures :

1. Number of Participants With Complete Remission With or Without Incomplete Platelet Recovery [ Time Frame: Day 42 post NK cell infusion ]
   To estimate the rate of complete remission with incomplete platelet recovery (CRp) - defined as leukemic clearance and neutrophil recovery without platelet recovery - by day 42 after the infusion of CD3/CD19 depleted, ALT-803 stimulated, donor NK cells and subcutaneous ALT-803 given after a non-myeloablative preparative regimen for the treatment of refractory or released acute myelogenous leukemia (AML)

Secondary Outcome Measures :

1. Incidence of in Vivo Expansion ≥100 of Donor Derived NK Cells Per /μl Blood [ Time Frame: Day 14 post NK cell infusion ]
   Number of patients with successful in vivo NK-cell expansion which is defined by measuring an absolute circulating donor-derived NK cell count of ≥100 cells/μl in patient's peripheral blood.
2. Number of Participants Experiencing ALT-803 Associated Toxicity [ Time Frame: Day 0 ]
   Toxicity will be classified and graded according to NCI's Common Terminology Criteria for Adverse Events V 4.0 (CTCAE)
3. Number of Participants Experiencing ALT-803 Associated Toxicity [ Time Frame: Day 5 ]
   Toxicity will be classified and graded according to NCI's Common Terminology Criteria for Adverse Events V 4.0 (CTCAE)
4. Number of Participants Experiencing ALT-803 Associated Toxicity [ Time Frame: Day 7 ]
   Toxicity will be classified and graded according to NCI's Common Terminology Criteria for Adverse Events V 4.0 (CTCAE)
5. Number of Participants Experiencing ALT-803 Associated Toxicity [ Time Frame: Day 10 ]
   Toxicity will be classified and graded according to NCI's Common Terminology Criteria for Adverse Events V 4.0 (CTCAE)
6. Number of Participants With Treatment Related Mortality [ Time Frame: 6 months post-therapy ]
   To evaluate the safety of the therapy as measured by rate of treatment related mortality (TRM) at 6 months

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:

  • Primary induction failure:

    • De novo AML - no CR after 2 or more chemotherapy induction attempts
    • Secondary AML (from MDS or treatment related): no CR after 1 or more chemotherapy induction attempts

  • Relapse after chemotherapy: not in CR after 1, 2, or 3 re-induction attempts

    • Patients > 60 years of age, the 1 cycle of chemotherapy is not required

  • Relapse after hematopoietic stem cell transplant:

    • Relapse must have occurred > 18 months after transplant
    • No re-induction required and no more than 1 re-induction attempt is allowed

• Notes:

  1. For hypomethylating agents (i.e. decitabine, azacitidine) to count as an induction/re-induction attempt, the patient must have completed a minimum of 3 monthly cycles
  2. For targeting agents (i.e. sorafenib) to count as an induction/re-induction attempt, the patient must have completed a minimum of 1 month without attaining CR
  3. 7+3 followed by 5+2 counts as TWO induction attempts
  4. Use of hydroxyurea is permitted to control blasts until Day -3 per Section 8.7
  5. A history of AML related CNS involvement is allowed if CSF analysis is negative on 2 test dates at least 2 weeks apart prior to study treatment. The use of ongoing CNS maintenance therapy is allowed while on study.
• HLA-haploidentical related donor (aged 12 to 75 years) with donor/recipient match based on a minimum of intermediate resolution DNA based Class I typing of the A and B locus (at least 2/4 class I allele)
• Karnofsky Performance Status ≥ 60%

• Adequate organ function within 14 days of study registration (28 days for pulmonary and cardiac) defined as:

  • Creatinine: ≤ 2.0 mg/dL
  • Hepatic: AST and ALT < 3 x upper limit of institutional normal
  • Pulmonary Function: oxygen saturation ≥ 90% on room air; PFT's required only if symptomatic or prior known impairment - must have pulmonary function >50% corrected DLCO and FEV1.
  • Cardiac Function: LVEF ≥ 40% by echocardiography, MUGA or cardiac MRI, no uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
• Able to be off prednisone or other systemic immunosuppressive medications for at least 3 days prior to NK cell infusion (excluding preparative regimen pre-medications) .
• Sexually active females of child bearing potential and males with partners of child bearing potential must agree to use effective contraception during therapy and for 4 months after completion of therapy .
• Voluntary written consent prior to the performance of any research related procedures.

Exclusion Criteria:

• Acute leukemias of ambiguous lineage
• Pregnant or breastfeeding - The agents used in this study include those that fall under Pregnancy Category D - have known teratogenic potential. Women of child bearing potential must have a negative pregnancy test at screening
• Active autoimmune disease requiring systemic immunosuppressive therapy
• History of severe asthma and currently on systemic chronic medications (mild asthma requiring inhaled steroids only is eligible)
• New or progressive pulmonary infiltrates on screening chest X-ray or chest CT scan unless cleared for study by Pulmonary. Infiltrates attributed to infection must be stable/improving (with associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections).
• Uncontrolled bacterial, fungal or viral infections including HIV-1/2 or active hepatitis C/B - chronic asymptomatic viral hepatitis is allowed
• Received any investigational agent within the 14 days before the start of study treatment (1st dose of fludarabine)
• Prior ALT-803

Contacts and Locations

Locations

United States, Minnesota

Masonic Cancer Center at University of Minnesota

Minneapolis, Minnesota, United States, 55455

Sponsors and Collaborators

Masonic Cancer Center, University of Minnesota

Investigators

• Principal Investigator: Jeffrey Miller, MD; Masonic Cancer Center, University of Minnesota

  Study Documents (Full-Text)

Documents provided by Masonic Cancer Center, University of Minnesota:

Study Protocol and Statistical Analysis Plan  [PDF] January 22, 2019

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Berrien-Elliott MM, Becker-Hapak M, Cashen AF, Jacobs M, Wong P, Foster M, McClain E, Desai S, Pence P, Cooley S, Brunstein C, Gao F, Abboud CN, Uy GL, Westervelt P, Jacoby MA, Pusic I, Stockerl-Goldstein KE, Schroeder MA, DiPersio JF, Soon-Shiong P, Miller JS, Fehniger TA. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy. Blood. 2022 Feb 24;139(8):1177-1183. doi: 10.1182/blood.2021011532.

• Responsible Party: Masonic Cancer Center, University of Minnesota
• ClinicalTrials.gov Identifier: NCT03050216
• Other Study ID Numbers: 2016LS056; MT2016-05 ( Other Identifier: Masonic Cancer Center, University of Minnesota )
• First Posted: February 10, 2017
• Results First Posted: November 27, 2020
• Last Update Posted: July 18, 2023
• Last Verified: July 2023

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases